The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Abstract
The human adenovirus E1B gene encodes a 55-kilodalton protein that inactivates the cellular tumor suppressor protein p53. Here it is shown that a mutant adenovirus that does not express this viral protein can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53. Ectopic expression of the 55-kilodalton EIB protein in the latter cells rendered them sensitive to infection with the mutant virus. Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors. These data raise the possibility that mutant adenoviruses can be used to treat certain human tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ruley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248
The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.
Scheffner, M., Münger, K., Byrne, J. C., & Howley, P. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5523 · Cited by 849
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
Yew, P. R., & Berk, A. J. (1992) · Nature · doi:10.1038/357082a0 · Cited by 561
Partial transformation of primary rat cells by the leftmost 4.5% fragment of adenovirus 5 DNA
Houweling, A., Van Den Elsen, P. J., & Van Der Eb, A. J. (1980) · Virology · doi:10.1016/0042-6822(80)90054-9 · Cited by 428
Analysis of the p53 gene and its expression in human glioblastoma cells.
Meir, E. G. V., Kikuchi, T., Tada, M., Li, H., Diserens, A., Wojcik, B. E., Huang, H., Friedmann, T., de Tribolet, N., & Cavenee, W. K. (1994) · PubMed · Cited by 327
(1993) · PubMed · Cited by 323
Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor
Dobner, T., Horikoshi, N., Rubenwolf, S., & Shenk, T. (1996) · Science · doi:10.1126/science.272.5267.1470 · Cited by 311
Righetti, S. C., Torre, G. D., Pilotti, S., Ménard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C. E., Cornarotti, M., Oriana, S., et al. (1996) · PubMed · Cited by 276
Cited by
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Legumes: Importance and Constraints to Greater Use
Graham, P. H., & Vance, C. P. (2003) · Plant Physiology · doi:10.1104/pp.017004 · Cited by 1,801
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Self-citationp53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Self-citationA mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Roulston, A., Marcellus, R. C., & Branton, P. E. (1999) · Annual Review of Microbiology · doi:10.1146/annurev.micro.53.1.577 · Cited by 749
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Immunotherapy for glioma: Current management and future application
Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 746
Why do viruses cause cancer? Highlights of the first century of human tumour virology
Moore, P. S., & Chang, Y. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2961 · Cited by 745
Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
Persistent effects of pre-Columbian plant domestication on Amazonian forest composition
Levis, C., Costa, F. R. C., Bongers, F., Peña-Claros, M., Clement, C. R., Junqueira, A. B., Neves, E. G., Tamanaha, E. K., Figueiredo, F. O. G., Salomão, R. P., et al. (2017) · Science · doi:10.1126/science.aal0157 · Cited by 694
An overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693
Reed, J. C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd726 · Cited by 643
Regulation of apoptosis by viral gene products
Teodoro, J. G., & Branton, P. E. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1739-1746.1997 · Cited by 629
Apoptosis and the Dilemma of Cancer Chemotherapy
Hannun, Y. A. (1997) · Blood · doi:10.1182/blood.v89.6.1845 · Cited by 605
Wirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
Update on adenovirus and its vectors
Russell, W. C. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2573 · Cited by 596
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Self-citationViral Vectors for Gene Therapy
Robbins, P. D., & Ghivizzani, S. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00020-5 · Cited by 529
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Choi, S., & Myers, J. N. (2008) · Journal of Dental Research · doi:10.1177/154405910808700104 · Cited by 516
To Die or Not to Die: An Overview of Apoptosis and Its Role in Disease
Hetts, S. W. (1998) · JAMA · doi:10.1001/jama.279.4.300 · Cited by 507
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Self-citationNemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Self-citationViral Vectors for Gene Transfer: A Review of Their Use in the Treatment of Human Diseases
Walther, W., & Stein, U. (2000) · Drugs · doi:10.2165/00003495-200060020-00002 · Cited by 442
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Replicative adenoviruses for cancer therapy
Alemany, R., Balagué, C., & Curiel, D. T. (2000) · Nature Biotechnology · doi:10.1038/77283 · Cited by 421
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Self-citationTranslating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium
Firestein, G. S., Echeverri, F., Yeo, M., Zvaifler, N. J., & Green, D. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10895 · Cited by 377
Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus
Berk, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209040 · Cited by 377
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 372
Self-citationViral carcinogenesis: revelation of molecular mechanisms and etiology of human disease
Butel, J. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.405 · Cited by 371
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & zur Hausen, H. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 353
Oncolytic viruses for cancer immunotherapy
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00922-1 · Cited by 351
Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301377 · Cited by 349
Self-citationCancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Self-citationGene Therapy: Promises and Problems
Pfeifer, A., & Verma, I. M. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.177 · Cited by 340
Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339
Quebrada Jaguay: Early South American Maritime Adaptations
Sandweiss, D. H., McInnis, H., Burger, R. L., Cano, A., Ojeda, B., Paredes, R., Sandweiss, M. D. C., & Glascock, M. D. (1998) · Science · doi:10.1126/science.281.5384.1830 · Cited by 337
Cancer gene therapy using a survivin mutant adenovirus
Mesri, M., Wall, N. R., Li, J., Kim, R. W., & Altieri, D. C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12983 · Cited by 337
Tsao, A. S., Kim, E. S., & Hong, W. K. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.3.150 · Cited by 331
Indigenous knowledge and the shackles of wilderness
Fletcher, M.-S., Hamilton, R., Dressler, W., & Palmer, L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022218118 · Cited by 318
Emerging Therapies for Hepatocellular Carcinoma (HCC)
Chakraborty, E., & Sarkar, D. (2022) · Cancers · doi:10.3390/cancers14112798 · Cited by 318
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
Antonio Chiocca, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc948 · Cited by 306
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Self-citationMechanisms of inhibitors of mutagenesis and carcinogenesis
De Flora, S. (1998) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(97)00292-3 · Cited by 304
Virus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299
Self-citationSur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Viral vectors for gene therapy
Robbins, P. D., Tahara, H., & Ghivizzani, S. C. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(97)01137-2 · Cited by 292
p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection
Goodrum, F. D., & Ornelles, D. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9479-9490.1998 · Cited by 289
Oncolytic viral therapies – the clinical experience
Aghi, M., & Martuza, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1209037 · Cited by 288
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 284
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Self-citationHallenbeck, P. L., Chang, Y.-N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., & Chiang, Y. L. (1999) · Human Gene Therapy · doi:10.1089/10430349950017725 · Cited by 283
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Role of α v Integrins in Adenovirus Cell Entry and Gene Delivery
Nemerow, G. R., & Stewart, P. L. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.3.725-734.1999 · Cited by 270
Telomerase-Specific Replication-Selective Virotherapy for Human Cancer
Kawashima, T., Kagawa, S., Kobayashi, N., Shirakiya, Y., Umeoka, T., Teraishi, F., Taki, M., Kyo, S., Tanaka, N., & Fujiwara, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1075-3 · Cited by 262
p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication
Harada, J. N., & Berk, A. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5333-5344.1999 · Cited by 259
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Reid, T., Warren, R., & Kirn, D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700539 · Cited by 258
Self-citationSu, Z.-Z., Madireddi, M. T., Lin, J. J., Young, C. S. H., Kitada, S., Reed, J. C., Goldstein, N. I., & Fisher, P. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14400 · Cited by 254
Ki67 targeted strategies for cancer therapy
Yang, C., Zhang, J., Ding, M., Xu, K., Li, L., Mao, L., & Zheng, J. (2018) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1774-3 · Cited by 254
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Predicting pre-columbian anthropogenic soils in amazonia
McMichael, C. H., Palace, M. W., Bush, M. B., Braswell, B., Hagen, S., Neves, E. G., Silman, M. R., Tamanaha, E. K., & Czarnecki, C. (2014) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2013.2475 · Cited by 179
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Adenoviral vector-based strategies against infectious disease and cancer
Zhang, C., & Zhou, D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1165908 · Cited by 110
“Furthermore, Ads can be genetically modified to induce the apoptosis of the cancer cells, which are known as the oncolytic Ads.3,4 Ads are not only generally safe and can replicate in almost all the living cells, but also can be expanded easily inHEK293 cells and purified byCsCl gradient ultracentrifuge, and administe…”
BackgroundInfluentialTranslational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
“In the adenovirus Onyx-015 (Onyx Pharmaceuticals), the p53inhibitory protein E1B has been deleted, resulting in the specific replication in tumour cells with an inactivated p53 pathway (Bischoff et al., 1996; Heise et al., 1997).”
BackgroundFujiwara, T., Kagawa, S., Kishimoto, H., Endo, Y., Hioki, M., Ikeda, Y., Sakai, R., Urata, Y., Tanaka, N., & Fujiwara, T. (2006) · International Journal of Cancer · doi:10.1002/ijc.21846 · Cited by 73
Palanca-Wessels, M. C., Barrett, M. T., Galipeau, P. C., Rohrer, K. L., Reid, B. J., & Rabinovitch, P. S. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70480-9 · Cited by 67
Wirth, T., Kühnel, F., Fleischmann-Mundt, B., Woller, N., Djojosubroto, M., Rudolph, K. L., Manns, M., Zender, L., & Kubicka, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3664 · Cited by 65
Gene Therapy for Human Malignant Brain Tumors
Rainov, N. G., & Ren, H. (2003) · The Cancer Journal · doi:10.1097/00130404-200305000-00006 · Cited by 48
Metadata
- Authors
- Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., & McCormick, F.
- Venue
- Science
- Published
- 1996-10-18
- Volume
- 274
- Issue
- 5286
- Pages
- 373-376
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2016080258
- Cited by
- 1,760
- References
- 22
- FWCI
- 40.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.